Table 2.
Symptom scoring and summary
| Responders | Nonresponders | Total | |
|---|---|---|---|
| BPS type 1A | 6 | 1 | 7 |
| BPS type 3C | 7 | 3 | 10 |
| Total, n (%) | 13 (76.5) | 4 (23.5) | 17 (100) |
| Immediate response | |||
| Onset (h) | 4.2 | – | – |
| Duration (d) | 9.1 | – | – |
| Treatment effects | |||
| Frequency (night) | |||
| Before (Pre) | 13.6 (4.3) | 13.8 (3.8) | 12.9 (4.3) |
| After (Post) | 6.1 (1.5) **, *** | 13.3 (3.4) NS | 8.0 (1.9) **, *** |
| Pain | |||
| Before (Pre) | 5.2 | 5.1 | 5.1 |
| After (Post) | 1.0 *** | 4.4 NS | 1.8 *** |
| Quality of life | |||
| Before (Pre) | 5.2 | 5.0 | 5.1 |
| After (Post) | 1.0 *** | 4.3 NS | 1.8 *** |
| O'Leary symptom index | |||
| Before (Pre) | 17.4 | 17.5 | 17.4 |
| After (Post) | 4.6 ** | 16.0 NS | 7.2 *** |
| O'Leary problem index | |||
| Before (Pre) | 15.4 | 15.0 | 15.4 |
| After (Post) | 3.9 ** | 15.0 NS | 6.5 *** |
| Long-term treatment observation | 174.6 | ||
BPS = Bladder pain syndrome; NS = nonsignificant (Wilcoxon signed rank test).
See also Supplementary Table 2 for full details.
**
p < 0.01, Wilcoxon signed rank test.
***
p < 0.001, Wilcoxon signed rank test.